Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:skincare_product
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:drug
|
| gptkbp:application |
hip
|
| gptkbp:appointed_by |
applying to the skin
|
| gptkbp:approves |
gptkb:2006
gptkb:FDA |
| gptkbp:brand |
gptkb:Daytrana
|
| gptkbp:clinical_trial |
enhances focus
studies on pediatric use studies on efficacy studies on safety studies on pharmacokinetics studies on long-term use improves attention reduces hyperactivity |
| gptkbp:contains |
gptkb:drug
|
| gptkbp:contraindication |
gptkb:sneaker
heart problems history of substance abuse |
| gptkbp:duration |
up to 9 hours
after 9 hours |
| gptkbp:education |
potential side effects
how to apply the patch how to remove the patch importance of adherence to prescribed regimen what to do if a dose is missed |
| gptkbp:formulation |
matrix patch
|
| gptkbp:frequency |
once daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daytrana patch
|
| gptkbp:interacts_with |
antidepressants
MAO inhibitors antihypertensives |
| gptkbp:is_available_in |
different dosages
|
| gptkbp:is_involved_in |
ADHD patients
|
| gptkbp:is_monitored_by |
gptkb:weight
blood pressure heart rate |
| gptkbp:is_used_for |
treatment of ADHD
|
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
single-use pouches
|
| gptkbp:population |
children and adolescents
|
| gptkbp:regulatory_compliance |
prescription only
|
| gptkbp:release_date |
morning
|
| gptkbp:shelf_life |
up to 24 months
|
| gptkbp:side_effect |
anxiety
nausea decreased appetite insomnia dry mouth |
| gptkbp:storage |
room temperature
|
| gptkbp:technique |
CNS stimulant
|
| gptkbp:treatment |
through the skin
|